It’s not about crapping all over management. Someone called someone else an armchair CEO but the truth is this is the first CEO job Nader has ever had. There is a big difference between a good founder and a good CEO I give him all the credit in the world for having the vision to see Leronlimab for what it could be but by the same token it is also his responsibility to navigate FDA, NIH and foreign bureaucracies.

On an unrelated issue has anybody heard anything about an EUA from the United Kingdom?... aren’t they buy their own timetable supposed to have given some kind of answer by now?